We love to hear from our listeners. Send us a message. REGENXBIO's VP of Regulatory and Science Policy, Nina Hunter, Ph.D., shares potential solutions to gene therapies' regulatory roadblocks and why the accelerated approval pathway is so pertinent. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. Selecta Biosciences' President and CEO Dr. Carsten Brunn details the company's ImmTOR platform, which can mitigate unwanted immune responses that cause immune-related toxicities that impose significant treatment challenges with current therapies. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. Cellevolve Bio's founder and CEO. Dr. Derrell Porter shares his experience with starting up a cell therapy company and why we, as an industry, need to advocate for more Black leaders and leaders of color in the biotech industry. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. Dr. Michael Singer, CSO at Cartesian Therapeutics, details why RNA has advantages over other cell therapies, the company's three RNA trials, and the therapeutic benefit of multiple modifications. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. Vor Biopharma's CEO Dr. Robert Ang explains the company's lead engineered hematopoietic cell (eHSC) product candidate, genome engineering of HSCs, and the cell manufacturing process needed to leverage genome engineering technologies for the cells they're creating. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. Fernanda Copeland, Global Head, Patient Advocacy & Engagement at AVROBIO, explains how to incorporate community education, patient feedback, and more to improve clinical trial development and recruitment. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. Carisma Therapeutics’ Dr. Barton breaks down the latest in CAR-M technology as well as the company's Phase 1 First-in-Human Study of Adenovirally Transduced Anti-HER2 CAR Macrophages in Subjects with HER2 Overexpressing Solid Tumors. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. XyloCor Therapeutics' EXACT clinical trial is a Phase 1/2 multicenter, open-label, single arm, dose escalation trial for coronary artery disease — the most common type of heart disease — with gene therapy at its center. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. Dr. Amy Nicole Nayar, VP of US Patient Advocacy and Government Affairs at Novartis Gene Therapies explains what patient engagement should encompass in the cell and gene field as well as the unique challenges cell and gene therapy companies face where a patient engagement officer provides essential help. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. BridgeBio's CEO of Gene Therapy, Dr. Eric David, explains the company's gene therapy programs for Canavan disease and congenital adrenal hyperplasia, their manufacturing plans, and the platform underpinning their novel approach to gene therapy. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. Spark Therapeutics' Clinical Development Lead, Hematology, Dr. Tiffany Chang explains the company's data from its ongoing Phase 1/2 clinical trial of investigational SPK-8011 for hemophilia A, the largest gene therapy trial in this disease to date as well as the misconceptions and unknowns about the disease. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. Karen Kozarsky, Ph.D., Co-Founder and CSO of SwanBio, explains how the company is pioneering a deep and varied pipeline of gene therapies for genetically defined neurological diseases with a focus on the spinal cord. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. Bob Levis was diagnosed with Chronic Lymphocytic Leukemia in 2002 and was one of the early experimental trial participants at Penn Medicine for Dr. Carl June’s CAR-T therapy. Bob shares his remarkable journey with CLL as well as his important work with the CLL Society. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. Dr. Murat Kalayoglu, CEO at Cartesian Therapeutics, details the cell and gene therapy sector’s advancements in RNA cell therapy and the why behind the company's decision to build its own wholly-owned GMP manufacturing facility. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. University of Pennsylvania’s Dr. Bruce Levine explains his road to adoptive immunotherapy trials, overcoming the gap between academia and industry, and how Philadelphia earned the "Cellicon Valley" name for its continued innovation in cell and gene therapy — and more. Subscribe to the podcast! Apple | Spotify | YouTube...
We love to hear from our listeners. Send us a message. In this episode of Cell & Gene: The Podcast, University of Pennsylvania Health System’s CEO Kevin Mahoney talks to Host Erin Harris about how hospital systems must evolve to meet the needs of cell and gene therapy patients as these complex therapies are commercialized. They discuss what comprises UPHS and the ongoing innovation it brings to advanced therapies as well as how the Health System stays patient-focused at all costs. Subscribe ...
We love to hear from our listeners. Send us a message. During this first episode of Cell & Gene: The Podcast, Host Erin Harris talks to Enzyvant’s CEO Rachelle Jacques about the biotech’s lead asset, investigational regenerative therapy RVT-802 for congenital athymia. Jacques provides an update on FDA approval and details what’s next for RVT-802. She explains tissue-based therapies — how far they’ve come and the work that’s left to be done. And, they discuss what being patient-focused means ...
We love to hear from our listeners. Send us a message. Cell & Gene , the online resource that delivers in-depth content from authoritative authors and sources to professionals in the CGT sector, is thrilled to introduce “Cell & Gene: The Podcast.” Cell and gene therapies offer huge potential to treat a wide range of diseases and their possibilities represent a new era in medicine. “Cell & Gene: The Podcast” will explore approved and pipeline therapies, new trends in manufacturing, th...
